Before today, the Modern biotech company reported positive results from a Phase 1 study of its experimental vaccine COVID-19 to start below the first was in mid-March to test in healthy volunteers. The study, conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, included 45 healthy people who get a different three doses of vaccine. After Modern There are encouraging signs that antibodies against the coup seen in the plasma of people COVID-19 virus, SARS-CoV-2, in plans that have been generated as a similar or higher than those obtained from infection. The phase 1 is not actually measure the effectiveness of vaccination focuses primarily on safety. However, the evidence for the effectiveness of the thresholds of the study are encouraging. the height of antibodies seen in the participants show that the vaccine and trails attract the immune response of the body a defense against SARS-CoV-2 to assemble. The data also indicated that higher doses triggered stronger immune responses. In addition, such as to counteract the company reports in a first analysis, the antibodies eight of the subscriber (the low dose of four four, the average dose) appeared the virus in the laboratory. “Frankly, we have seen this data … and were pretty excited,” says Dr. Stephen Hoge, President of Modern. He hit on almost every point we could hope for. What these results show that the vaccine to the best of their ability to work, to test a vaccine against a phase 3 trial [the final]. And by works, means that produces a high quality, neutralizing antibody responses. The truth is that we have an own product and the protective immune response potential here. “In the Phase 1 study, the participants all the healthy subjects were 18:55 years. Those who are in the low and mid dose groups received two doses of about a month apart, in order to properly prime the immune system more robust reaction. people in the highest dose group received a single vaccination. the results are likely to be analyzed and reported in a scientific journal in the coming weeks . on the basis of these results, the study of phase 2 has cleared, the Food and Drug Administration (FDA), approximately 600 healthy volunteers are entered, only are included two doses-on, which is a bit ‘higher than the lowest dose and the average dose, appears as it is sufficient to generate a relatively strong immune response. the company expects that these studies begin in June and for those with a higher risk of exposure to SARS-CoV-2 as employees include health care. These studies will determine what dose is 3 phase clinical trials have tested in the past, which could begin as early as July. Based on the urgent need for a vaccine against COVID-19, on May 12, the FDA has granted fast track status Modern vaccine, which would accelerate the supervisor of the review process. These results, although still too early are a validation of modern technology ranging from the design of traditional vaccines that are generally linked to activate the immune system of the fragments of viral proteins or inactivated virus. Modern vaccine comprises mRNA from viruses, the genetic material that codes for proteins; after vaccination can cause the body’s immune cells as foreign and it recognizes each launch attacks against them. The company develops mRNA vaccines against a number of other diseases, including respiratory syncytial virus, Zika and influence.
Modern COVID-19 vaccine shows promise to generate positive immune responses in a first study
